Understand the source comparison
Best Research Peptides for IBS: Mechanism Comparison
BPC-157 Angiogenesis and mucosal repair VEGF receptor activation, nitric oxide signaling 10 mcg/kg–10 mg/kg daily Moderate. Multiple animal studies, no human RCTs Best studied for structural repair; oral bioavailability contested KPV Cytokine suppression NF-κB
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Angiogenesis and mucosal repair
- VEGF receptor activation, nitric oxide signaling
- 10 mcg/kg–10 mg/kg daily
- Moderate. Multiple animal studies, no human RCTs
- Best studied for structural repair; oral bioavailability contested
- KPV
- Cytokine suppression
- NF-κB inhibition at tight junctions
- 1–5 mg/kg daily
- Limited. Fewer studies than BPC-157, promising anti-inflammatory data
- Addresses inflammation upstream; short half-life complicates dosing
- LL-37
- Antimicrobial and microbiome modulation
- Cathelicidin pathway, selective bacterial inhibition
- 0.5–2 mg/kg daily
- Emerging. Strong microbiome data, minimal IBS-specific trials
- Targets dysbiosis; stability and delivery challenges remain
- Larazotide (AT-1001)
- Tight junction stabilization
- Zonulin pathway antagonism
- 0.5–12 mg orally (human trials)
- Strongest. Phase IIb completed for celiac, IBS trials ongoing
- Only peptide with human data; not yet FDA-approved for IBS
- Pentadecapeptide combos
- Multi-pathway (repair + inflammation + microbiome)
- Varies by formulation
- Protocol-dependent
- Theoretical. Limited published combo studies
- Reflects IBS complexity but lacks controlled evidence